Reports Q4 revenue $277.0M, consensus $287.47M. “Our FY24 delivered stable earnings and cash flow, enabled by our leading brand portfolio and proven business strategy. However, our fourth quarter performance was affected by accelerated supply chain pressures late in the quarter, mainly in eye care products, that limited our ability to meet retailer order demand. Despite this, our long-term business fundamentals remain solid, with strong consumption during the fiscal year above our long-term expectations as well as solid cash flow which provides many options to create long-term shareholder value.” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- PBH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Prestige Consumer Healthcare Elects Pfizer Veteran John F. Kelly to Board
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results
- Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag